Peptide Inhibitors for SARS-CoV-2 Methyltransferase

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

The USPTO granted Patent US12605423B2 to United Arab Emirates University for synthetic peptide inhibitors designed to inhibit SARS-CoV-2 replication through targeting of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14) for COVID-19 treatment. The patent covers Peptide P3, a synthetic analog of amino acids 89-96 of the SARS-CoV-2 non-structural protein 10 (NSP10), modified to enhance cell membrane penetration.